Pluri Inc. – NASDAQ:PLUR

Pluri stock price today

$4.83
+0.28
+6.15%
Financial Health
0
1
2
3
4
5
6
7
8
9

Pluri stock price monthly change

-20.73%
month

Pluri stock price quarterly change

-20.73%
quarter

Pluri stock price yearly change

+725.77%
year

Pluri key metrics

Market Cap
25.07M
Enterprise value
27.56M
P/E
-0.92
EV/Sales
85.35
EV/EBITDA
-0.86
Price/Sales
91.46
Price/Book
1.27
PEG ratio
N/A
EPS
-6.08
Revenue
N/A
EBITDA
-27.97M
Income
-28.58M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-10292.57%
Oper. margin
-8136.22%
Gross margin
0%
EBIT margin
-8136.22%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Pluri stock price history

Pluri stock forecast

Pluri financial statements

Pluri Inc. (NASDAQ:PLUR): Profit margin
Jun 2022 0 -9.20M
Mar 2023 87K -7.62M -8763.22%
Jun 2023 111K -6.45M -5818.92%
Mar 2024 71K -5.29M -7454.93%
Pluri Inc. (NASDAQ:PLUR): Analyst Estimates
2026 12.55M -22.35M -178.06%
  • Analysts Price target

  • Financials & Ratios estimates

Pluri Inc. (NASDAQ:PLUR): Earnings per share (EPS)
2022-11-10 -0.1128 -0.19
2023-02-13 -0.24 -0.24
Pluri Inc. (NASDAQ:PLUR): Debt to assets
Dec 2022 59927000 34.96M 58.34%
Mar 2023 56241000 35.36M 62.87%
Jun 2023 50797000 35.49M 69.88%
Mar 2024 36390000 34.54M 94.93%
Pluri Inc. (NASDAQ:PLUR): Cash Flow
Jun 2022 -8.42M -2.95M -1.24M
Mar 2023 -6.07M -1.68M 2.34M
Jun 2023 -2.89M 4.32M -10K
Mar 2024 -4.20M 5.66M 0

Pluri alternative data

Pluri Inc. (NASDAQ:PLUR): Employee count
Aug 2023 154
Sep 2023 154
Oct 2023 154
Nov 2023 154
Dec 2023 123
Jan 2024 123
Feb 2024 123
Mar 2024 123
Apr 2024 123
May 2024 123
Jun 2024 123
Jul 2024 123

Pluri other data

1.36% -0.77%
of PLUR is owned by hedge funds
452.49K -242.07K
shares is hold by hedge funds

Pluri Inc. (NASDAQ:PLUR): Insider trades (number of shares)
Period Buy Sel
Feb 2022 80616 0
Dec 2022 0 2000
Transaction Date Insider Security Shares Price per share Total value Source
Sale
ABERMAN ZAMI director Common Stock 2,000 $0.97 $1,940
Purchase
ABERMAN ZAMI director Common Stock 80,616 $1.8 $145,109
Sale
CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 10 percent owner
Common stock 45,000 $3.72 $167,400
Sale
CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 10 percent owner
Common stock 70,007 $3.72 $260,426
Sale
CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 10 percent owner
Common stock 24,110 $3.69 $88,966
Sale
CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 10 percent owner
Common stock 71,775 $3.69 $264,850
Sale
CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 10 percent owner
Common Stock 22,015 $3.69 $81,235
Sale
CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 10 percent owner
Common Stock 122,663 $3.68 $451,400
Sale
CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 10 percent owner
Common stock 261,238 $3.84 $1,003,154
Sale
CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 10 percent owner
Common Stock 79,300 $3.83 $303,719
Thursday, 19 December 2024
globenewswire.com
Tuesday, 12 November 2024
accesswire.com
Monday, 11 November 2024
prnewswire.com
Tuesday, 23 July 2024
newsfilecorp.com
Thursday, 18 July 2024
globenewswire.com
Tuesday, 18 June 2024
globenewswire.com
Thursday, 6 June 2024
globenewswire.com
Monday, 20 May 2024
globenewswire.com
Thursday, 2 May 2024
globenewswire.com
Monday, 8 April 2024
globenewswire.com
Thursday, 28 March 2024
GlobeNewsWire
Monday, 31 October 2022
GlobeNewsWire
  • What's the price of Pluri stock today?

    One share of Pluri stock can currently be purchased for approximately $4.83.

  • When is Pluri's next earnings date?

    Unfortunately, Pluri's (PLUR) next earnings date is currently unknown.

  • Does Pluri pay dividends?

    No, Pluri does not pay dividends.

  • How much money does Pluri make?

    Pluri has a market capitalization of 25.07M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 13.59% to 326K US dollars. Pluri made a loss 20.89M US dollars in net income (profit) last year or -$0.24 on an earnings per share basis.

  • What is Pluri's stock symbol?

    Pluri Inc. is traded on the NASDAQ under the ticker symbol "PLUR".

  • What is Pluri's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Pluri?

    Shares of Pluri can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Pluri have?

    As Jul 2024, Pluri employs 123 workers.

  • When Pluri went public?

    Pluri Inc. is publicly traded company for more then 22 years since IPO on 30 Jun 2003.

  • What is Pluri's official website?

    The official website for Pluri is pluri-biotech.com.

  • How can i contact Pluri?

    Pluri can be reached via phone at +972 74 710 8600.

Pluri company profile:

Exchange:

NASDAQ

Full time employees:

106

Industry:

Biotechnology

Sector:

Healthcare

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Building No. 5
Haifa, 3508409

CIK: 0001158780
ISIN: US72942G1040
CUSIP: 72942G104